Moreover, imatinib impairs CD8+ T cells specifically directed against leukemia-associated antigen function in vitro; therefore, clinical imatinib administration may result in reduction of the efficacy of the graft-versus-leukemia effect or other T-cell-based immunotherapies[15]. The gene discussed is CD8A; the disease is leukemia.